"Merck on Thursday announced that its blockbuster PD-1 inhibitor Keytruda (pembrolizumab) fell short of its dual primary endpoints in the Phase III KEYLYNK-006 trial, unable to significantly improve survival outcomes in specific patients with metastatic non-squamous non-small cell lung cancer." the article says.
https://www.biospace.com/article/merck-s-keytruda-continues-losing-streak-in-nsclc-with-phase-iii-flop/?utm_campaign=Daily%20Social%20%7C%20News&utm_content=286824601&utm_medium=social&utm_source=linkedin&hss_channel=lcp-424124
bisantrene could be Keytruda's saviour...
- Forums
- ASX - By Stock
- Industry news
"Merck on Thursday announced that its blockbuster PD-1 inhibitor...
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.23 |
Change
0.005(0.41%) |
Mkt cap ! $201.9M |
Open | High | Low | Value | Volume |
$1.22 | $1.25 | $1.19 | $74.76K | 60.81K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 5549 | $1.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.27 | 9714 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 850 | 1.210 |
1 | 1 | 1.205 |
1 | 1365 | 1.200 |
2 | 2284 | 1.190 |
2 | 3500 | 1.180 |
Price($) | Vol. | No. |
---|---|---|
1.225 | 1550 | 2 |
1.235 | 425 | 1 |
1.255 | 415 | 1 |
1.270 | 8460 | 1 |
1.275 | 1300 | 1 |
Last trade - 13.13pm 08/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.24 |
  |
Change
0.005 ( 4.20 %) |
|||
Open | High | Low | Volume | ||
$1.22 | $1.27 | $1.20 | 14481 | ||
Last updated 13.37pm 08/05/2024 ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online